中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | JN060016 |
|---|---|
| 説明 |
Tefibazumab (JN060016) is a research-grade recombinant antibody targeting clfAClumping factor A. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 種反応性 | Staphylococcus aureus |
| アプリケーション | ELISA, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG1-kappa |
| 発現システム | Mammalian cells |
| ターゲット | clfA Clumping factor A |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% purity as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | Q53653, Q2G015, Q5HHM8 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | Aurexis, 521079-87-8 |
| 背景 | Clumping factor A (clfAClumping factor A) is a ~97 kDa protein. Cell surface-associated protein implicated in virulence. Promotes bacterial attachment exclusively to the gamma-chain of human fibrinogen. Induces formation of bacterial clumps, which diminish the ability of group IIA phospholipase A2 to cause bacterial phospholipid hydrolysis and killing. Significantly decreases macrophage phagocytosis possibly thanks to the clumps, clumped bacteria being too large to be phagocytosed. Dominant factor responsible for human platelet aggregation, which may be an important mechanism for initiating infective endocarditis. |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Tefibazumab.
SDS-PAGE for Research Grade Tefibazumab.
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
